Venlafaxine Dosing for Tension-Type Headache
The evidence does not support venlafaxine as a first-line treatment for tension-type headache (TTH), and there is no established standard dose for this indication. However, when used off-label for chronic TTH prophylaxis, the most commonly studied and effective dose is 150 mg/day of extended-release venlafaxine.
Evidence-Based Dosing Recommendations
Starting and Target Doses
Based on the available research evidence for TTH specifically:
- Starting dose: 37.5 mg once or twice daily 1, 2
- Target dose: 150 mg/day 1, 2
- Titration: Increase by 75 mg weekly as tolerated 3
- Maximum studied dose: 225 mg/day 3, 4
- Duration of adequate trial: 4-6 weeks at target dose 3
The randomized controlled trial by Tarlaci (2007) demonstrated that venlafaxine XR 150 mg/day significantly reduced headache days compared to placebo in TTH patients (number needed to treat = 3.48) 1. This represents the highest quality evidence for venlafaxine in TTH.
Clinical Context and Limitations
Important Caveats
Venlafaxine is NOT a guideline-recommended treatment for TTH. The 2024 VA/DoD guidelines recommend amitriptyline as the only evidence-based preventive treatment for chronic TTH 5. The 2021 Nature Reviews primer on TTH lists amitriptyline, venlafaxine, and mirtazapine as recommended preventive treatments 6, but this represents expert opinion rather than strong guideline support.
When to Consider Venlafaxine
Venlafaxine may be appropriate for chronic TTH when:
- Amitriptyline is contraindicated, not tolerated, or ineffective 6
- Patient has comorbid depression or anxiety (though the RCT specifically excluded these patients) 1
- Tricyclic antidepressants are poorly tolerated due to anticholinergic effects
Dosing Adjustments
Hepatic impairment: Reduce total daily dose by 50% in mild-to-moderate hepatic impairment 4
Renal impairment:
Elderly patients: Use lower starting doses and slower titration; dose-corrected plasma concentrations are significantly higher (8.91 vs 5.52 nmol/L/mg in patients >64 years) 7
Safety Considerations
- Cardiac monitoring: Monitor blood pressure, as increases can occur; use caution in cardiac disease 3
- Withdrawal syndrome: Must taper when discontinuing 3
- Number needed to harm: 5.58 in the TTH trial, with 6/34 patients discontinuing due to adverse events 1
- Common side effects: Nausea (reduced by starting at 37.5 mg), insomnia, and dose-dependent effects 8, 9
Comparative Effectiveness
Recent migraine studies (not TTH) suggest venlafaxine has comparable efficacy to amitriptyline/nortriptyline but with fewer adverse effects 8, 9. However, these findings cannot be directly extrapolated to TTH, as the pathophysiology differs.
Bottom Line Algorithm
- First-line: Use amitriptyline for chronic TTH prophylaxis 5
- Second-line: If amitriptyline fails or is contraindicated, consider venlafaxine XR
- Dosing: Start 37.5 mg daily, titrate to 150 mg/day over 2-4 weeks
- Trial duration: Assess response after 4-6 weeks at target dose
- Monitoring: Check blood pressure, especially in patients with cardiac disease
The evidence base for venlafaxine in TTH remains limited to small studies and retrospective data 10, 1, 2, making it a reasonable but not preferred option for chronic TTH prophylaxis.